###begin article-title 0
###xml 74 78 74 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
Large-Scale Evaluation of Candidate Genes Identifies Associations between VEGF Polymorphisms and Bladder Cancer Risk
###end article-title 0
###begin p 1
###xml 431 435 431 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 446 447 446 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 504 506 504 506 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 578 583 578 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF,</italic>
###xml 1266 1267 1266 1267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1349 1353 1349 1353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 1845 1849 1845 1849 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
Common genetic variation could alter the risk for developing bladder cancer. We conducted a large-scale evaluation of single nucleotide polymorphisms (SNPs) in candidate genes for cancer to identify common variants that influence bladder cancer risk. An Illumina GoldenGate assay was used to genotype 1,433 SNPs within or near 386 genes in 1,086 cases and 1,033 controls in Spain. The most significant finding was in the 5' UTR of VEGF (rs25648, p for likelihood ratio test, 2 degrees of freedom = 1 x 10-5). To further investigate the region, we analyzed 29 additional SNPs in VEGF, selected to saturate the promoter and 5' UTR and to tag common genetic variation in this gene. Three additional SNPs in the promoter region (rs833052, rs1109324, and rs1547651) were associated with increased risk for bladder cancer: odds ratio (95% confidence interval): 2.52 (1.06-5.97), 2.74 (1.26-5.98), and 3.02 (1.36-6.63), respectively; and a polymorphism in intron 2 (rs3024994) was associated with reduced risk: 0.65 (0.46-0.91). Two of the promoter SNPs and the intron 2 SNP showed linkage disequilibrium with rs25648. Haplotype analyses revealed three blocks of linkage disequilibrium with significant associations for two blocks including the promoter and 5' UTR (global p = 0.02 and 0.009, respectively). These findings are biologically plausible since VEGF is critical in angiogenesis, which is important for tumor growth, its elevated expression in bladder tumors correlates with tumor progression, and specific 5' UTR haplotypes have been shown to influence promoter activity. Associations between bladder cancer risk and other genes in this report were not robust based on false discovery rate calculations. In conclusion, this large-scale evaluation of candidate cancer genes has identified common genetic variants in the regulatory regions of VEGF that could be associated with bladder cancer risk.
###end p 1
###begin title 2
Author Summary
###end title 2
###begin title 3

###end title 3
###begin p 4
###xml 365 372 365 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(VEGF).</italic>
###xml 545 549 545 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 652 656 652 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
This article reports findings from a large-scale evaluation of common variation in candidate genes for cancer to identify variants that influence bladder cancer risk. We first evaluated 1,433 common variants within or near 386 genes in a large case-control study in Spain. The most significant finding was the gene coding for the vascular endothelial growth factor (VEGF). To further investigate this finding, we identified markers that captured most common variation in the whole gene. Analyses indicated that variants in regulatory regions of VEGF could modify the risk for developing bladder cancer. This association is biologically plausible since VEGF is critical for the growth of new blood vessels, which is important for tumor development, and its elevated expression in bladder tumors correlates with tumor progression. Future studies are required to confirm these findings, as well as to investigate the mechanisms for the observed associations.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 197 198 197 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030029-b001">1</xref>
###xml 334 335 334 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030029-b001">1</xref>
###xml 517 521 517 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NAT2</italic>
###xml 526 531 526 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GSTM1</italic>
###xml 589 593 589 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NAT2</italic>
###xml 604 605 604 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030029-b002">2</xref>
###xml 626 631 626 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GSTM1</italic>
###xml 702 706 702 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NAT2</italic>
###xml 795 796 795 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030029-b002">2</xref>
###xml 82 89 <span type="species:ncbi:4097">tobacco</span>
Bladder cancer is primarily a sporadic disease, and environmental factors such as tobacco smoking and occupational exposure to aromatic amines have been established as strong determinants of risk [1]. A moderate familial component has been demonstrated for bladder cancer, but so far no high-penetrance mutations have been described [1]. However, there is strong evidence for the influence of common genetic variants on bladder cancer risk. Most notably, large studies have demonstrated associations with each of the NAT2 and GSTM1 genotypes and a probable interaction between smoking and NAT2 genotype [2]. Specifically, the GSTM1 null genotype increases the overall risk of bladder cancer; while the NAT2 slow acetylator genotype appears to increase risk particularly among cigarette smokers [2]. In this context, we hypothesized that a large-scale effort to screen common variants in candidate cancer genes could identify additional bladder cancer susceptibility genes.
###end p 6
###begin p 7
###xml 854 855 854 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030029-b003">3</xref>
The recent development of highly multiplexed single nucleotide polymorphism (SNP) genotyping assays has resulted in an opportunity to screen candidate genetic variants in an affordable, high-throughput manner in epidemiological studies. We used a GoldenGate assay by Illumina targeted to analyze over 1,500 SNPs in selected candidate cancer genes in order to identify bladder cancer susceptibility genes using samples collected in a large case-control study of bladder cancer in Spain. Because this was one of the first epidemiological studies using this highly multiplexed technology, we performed a detailed analysis of data quality. All SNPs chosen for this platform were drawn from the SNP500Cancer public database (), which includes genes or specific genetic variants that could be important in cancer and have been re-sequenced in 102 individuals [3].
###end p 7
###begin title 8
Results
###end title 8
###begin p 9
We obtained high-quality genotype calls from 1,433 SNP assays in or near 386 genes involved in cancer-related pathways, with a median of two SNPs per gene (range: 1-37 SNPs per gene). About half (51%) of these SNPs were located in introns, 32% in exons, 12% in promoter regions, and 5% in 3' of stop codon (STP). For SNPs located in exons, 5% were in 5' UTRs, 68% in coding regions (approximately half were synonymous and half non-synonymous changes) and 27% in 3' UTRs. The median (range) minor allele frequency (MAF) among controls was 0.24 (0.02-0.50).
###end p 9
###begin p 10
###xml 540 541 534 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 282 294 <span type="species:ncbi:9606">participants</span>
The global genotype completion for study samples was >/=99%. Genotype concordance in 69 blinded duplicate blood DNA pairs was >/=99%. Of the 1,433 SNPs in the GoldenGate assay, 72 SNPs had been previously typed using other genotyping platforms on 2,256 blood DNA samples from study participants, and 31 of these SNPs had been previously genotyped on 50 buccal DNA samples from the study. Genotype concordance between the GoldenGate and other platforms (primarily TaqMan) was >/=98%. About 5% (79/1433) of genotype assays had a significant (p < 0.05) departure from Hardy-Weinberg equilibrium, which is consistent with what would be expected by chance.
###end p 10
###begin p 11
###xml 12 19 12 19 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-0030029-t001">Table 1</xref>
###xml 36 44 36 44 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0030029-st001">Table S1</xref>
###xml 92 93 92 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 214 334 214 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF, STK11, CYP1B1, ZNF350, PTH, GHR, CASP9, PLA2G6, GSTA4, ROS1, RB1CC1, TERT, XRCC4, FZD7, CETP, CYP24A1, LIPC, ESR1,</italic>
###xml 339 347 339 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSD17B4.</italic>
###xml 361 381 361 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARHGDIB, SHBG, GPX4,</italic>
###xml 386 391 386 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STAT1</italic>
###xml 567 575 567 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0030029-st002">Table S2</xref>
Gene-based (Table 1) and SNP-based (Table S1) analyses showed promising associations (i.e., p-value for trend or likelihood ratio test [LRT]; 2 degrees of freedom [df] <0.01) with bladder cancer risk for 19 genes: VEGF, STK11, CYP1B1, ZNF350, PTH, GHR, CASP9, PLA2G6, GSTA4, ROS1, RB1CC1, TERT, XRCC4, FZD7, CETP, CYP24A1, LIPC, ESR1, and HSD17B4. In addition, ARHGDIB, SHBG, GPX4, and STAT1 showed significant associations with risk according to the LRT (2 df); however, estimates for heterozygous and homozygous variants showed associations in opposite directions (Table S2).
###end p 11
###begin p 12
###xml 12 13 12 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 38 39 38 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Global Gene p-values for Significant (p-value </= 0.01) Associations between Bladder Cancer and Common Genetic Variation in Selected Candidate Genes among the 1,086 Cases and 1,033 Controls in the Spanish Bladder Cancer Study
###end p 12
###begin p 13
###xml 147 153 147 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(VEGF)</italic>
###xml 160 167 160 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-0030029-t001">Table 1</xref>
###xml 257 278 257 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 299 303 299 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 432 433 432 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 522 528 522 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STK11,</italic>
###xml 712 716 712 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GHR,</italic>
###xml 742 747 742 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF.</italic>
The most significant association with bladder cancer risk according to gene-based analyses was observed for the vascular endothelial growth factor (VEGF) gene (Table 1). We evaluated these findings using the false discovery rate (FDR) approach described in Materials and Methods. FDR values for the VEGF association with bladder cancer risk, taking into account all 386 genes evaluated in this report, was 0.032 based on the global p-values from LRTs (2 df) performed for each gene. The next lowest FDR value was 0.56 for STK11, indicating that the associations for other genes were not robust. We also calculated FDR values for the 386 trend tests performed for each gene, and the lowest FDR value was 0.51 for GHR, with a value of 0.64 for VEGF.
###end p 13
###begin p 14
###xml 95 99 95 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 422 423 422 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 454 456 454 456 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 485 492 485 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-0030029-t002">Table 2</xref>
###xml 674 675 674 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 916 917 916 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030029-b004">4</xref>
###xml 1038 1039 1038 1039 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1074 1075 1074 1075 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Individual SNP analyses showed the strongest association for a variant allele in the 5' UTR of VEGF (rs25648, RefSNP accession number assigned by dbSNP, ). The MAF for this SNP among the control population was 0.14, and the odds ratio (OR) (95% confidence interval [CI]) for heterozygote and homozygote variant genotypes compared to the common homozygote genotype was 1.12 (0.91-1.37) and 5.11 (2.33-11.20), respectively; p-values for LRT (2 df) = 1 x 10-5 and for trend test = 0.002 (Table 2). The observed frequency for the homozygote variant genotype was lower than expected under Hardy-Weinberg equilibrium in the control population (0.8% observed versus 1.9% expected, p-value = 0.002), while genotype completion and concordance for this SNP were measured at 100%. To explore the impact of the observed departure on estimates of relative risk, we re-estimated ORs (95% CIs) assuming Hardy-Weinberg equilibrium [4]. Estimates for heterozygote and homozygote variant genotypes assuming Hardy-Weinberg equilibrium were 1.23 (1.02-1.48) p-value = 0.03 and 2.20 (1.48-3.28) p-value = 0.00009, respectively.
###end p 14
###begin p 15
###xml 29 33 29 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
Association between Selected VEGF Polymorphisms with Bladder Cancer Risk among 1,086 Cases and 1,033 Controls in the Spanish Bladder Cancer Study
###end p 15
###begin p 16
###xml 50 54 50 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 412 416 412 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 563 567 563 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 608 609 608 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 769 773 769 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 848 855 848 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-0030029-t002">Table 2</xref>
###xml 1070 1071 1068 1069 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 1071 1072 1069 1070 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1169 1177 1165 1173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-0030029-t002">Tables 2</xref>
###xml 1179 1181 1175 1177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0030029-st003">S3</xref>
###xml 1187 1189 1183 1185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0030029-st004">S4</xref>
We performed additional genotyping for 29 SNPs in VEGF (including the three SNPs previously genotyped) in an effort to dissect the locus to follow-up findings from our exploratory analysis described above. Two of these SNPs showed low genotypic variation in this population (no variants were observed for rs3024989, and three controls and no cases were heterozygote for rs9367173). The concordance for the three VEGF SNPs previously genotyped in the GoldenGate assay (rs1005230, rs25648, and rs3025039) was 100%. Genotype completion and concordance rates for all VEGF SNPs exceeded 99%, and all but rs25648 (p = 0.002) were in Hardy-Weinberg equilibrium in controls. Analyses showed significant associations with three additional SNPs located in the promoter region of VEGF (rs833052, rs1109324, and rs1547651) and one SNP in intron 2 (rs3024994) (Table 2). However, the association for the rs833052 promoter SNP was only borderline significant. Two of these SNPs (rs1109324 and rs1547651) were in strong linkage disequilibrium (LD) with the 5' UTR SNP (D' >/= 0.94 and r2 >/= 0.84). None of the other SNPs showed significant associations with bladder cancer risk (see Tables 2, S3, and S4 for more details).
###end p 16
###begin p 17
###xml 38 42 38 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 233 237 233 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NAT2</italic>
###xml 242 247 242 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GSTM1</italic>
###xml 336 340 336 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 424 425 424 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 483 491 483 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0030029-st005">Table S5</xref>
###xml 587 592 587 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GSTM1</italic>
###xml 608 609 608 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 643 651 643 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0030029-st005">Table S5</xref>
We evaluated interactions between the VEGF SNPs significantly associated with bladder cancer risk and other determinants of risk (i.e., age, gender, smoking status, family history of cancer in at least one first-degree relative, and NAT2 and GSTM1 genotypes). Analyses suggested stronger associations for the two correlated SNPs in the VEGF promoter (rs1109324 and rs1547651) among subjects with a family history of cancer (p-value for heterogeneity = 0.035 and 0.036, respectively; Table S5). We also observed a stronger association for the 5' UTR SNP (rs25648) among subjects with the GSTM1 null genotype (p-value for heterogeneity = 0.031; Table S5). However, these findings need to be interpreted with caution given the number of interactions evaluated.
###end p 17
###begin p 18
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 196 204 196 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030029-g001">Figure 1</xref>
###xml 351 352 351 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 405 413 405 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030029-g002">Figure 2</xref>
Haplotype analyses were based on 27 VEGF SNPs (of the 29 SNPs determined, two were excluded because of low genotypic variation). Of the three large blocks defined by LD in our control population (Figure 1), we observed significant associations between haplotypes and risk for bladder cancer in two LD blocks, including the promoter and 5' UTR (global p = 0.023 and 0.043 for blocks 1 and 2, respectively; Figure 2). Consistent with individual SNP analyses, the AT haplotype in block 1 carrying the variant allele for rs833052 was associated with increased bladder cancer risk; however, the CT haplotype was related to decreased bladder cancer risk, which was not predicted by individual SNP analyses. Both the individual SNP and haplotype associations were only of borderline significance and thus could be due to chance.
###end p 18
###begin title 19
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
Gene Map and LD Plot of VEGF Gene
###end title 19
###begin p 20
Color scheme is based on D' and logarithm of the odds of linkage (LOD) score values: white D' < 1 and LOD < 2, blue D' = 1 and LOD < 2, shades of pink/red: D' < 1 and LOD >/= 2, and bright red D' = 1 and LOD >/= 2. Numbers in squares are D' values (values of 1.0 are not shown). Block definition is based on the Gabriel et al. method [34]. Two (rs3024989 and rs367173) of the 29 SNPs determined are not shown because of low variation in this population. Red rectangles in the gene map represent exons.
###end p 20
###begin title 21
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
Phylogenetic Trees for VEGF Haplotypes and Association with Bladder Cancer Risk among 926 Cases and 900 Controls with DNA in the iPLEX Assay, Spanish Bladder Cancer Study
###end title 21
###begin p 22
###xml 4 12 4 12 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030029-g001">Figure 1</xref>
###xml 46 50 46 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 235 243 235 243 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs833052</bold>
###xml 268 277 268 277 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs1109324</bold>
###xml 279 288 279 288 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs1547651</bold>
###xml 353 360 353 360 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs25648</bold>
###xml 393 402 393 402 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs3024994</bold>
See Figure 1 for block definitions. Of the 29 VEGF SNPs determined, two had low genotypic variation in our population; therefore, haplotype analyses were based on the remaining 27 SNPs. Polymorphic bases are in 5' to 3' order: Block 1(rs833052 and rs866236); Block 2 (rs1109324, rs1547651, rs833060, rs699947, rs1005230, rs833061, rs1570360, rs2010963, rs25648, rs833067, rs3025042, rs833068, rs3024994, rs735286, rs3024998, rs3025000, and rs3025006); and Block 3 (rs3025030, rs3025033, rs3025035, and rs3025036). Bolded rs numbers are for individual SNPs significantly associated with bladder cancer risk.
###end p 22
###begin p 23
Eleven cases and 13 controls with missing data on more than 15 of the 17 SNPs in Block 2 were excluded from haplotype analyses because their inclusion resulted in lack of convergence. Nucleotide changes significantly associated with risk in the individual genotype analyses are shown in boxes. The most common haplotye is the reference category. Haplotypes with the common variant for each individual SNP are CC for Block 1, GAGCCGTGCTGGCCCCC for Block 2, and GACC for Block 3.
###end p 23
###begin p 24
###xml 169 177 169 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030029-g002">Figure 2</xref>
###xml 663 671 663 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030029-g002">Figure 2</xref>
Of the nine observed haplotypes in block 2, only one (GAGCCGTGCTGGTCCCT) carried the variant in intron 2 (rs3024994) that was individually associated with reduced risk (Figure 2). Consistent with SNP analyses, this haplotype was also associated with a reduction in risk. Two other haplotypes carried at least one variant for three correlated SNPs individually associated with risk (rs1109324, rs1547651, and rs25648). Both haplotypes were associated with increases in risk, although the association for the haplotye carrying only the rs25648 variant (GAGATGCGTCGGCCCCC) was not significant, possibly due to its low frequency in the population (1.0% of controls) (Figure 2). Therefore, haplotype analyses cannot help distinguish which of the three correlated SNPs is most important in determining risk.
###end p 24
###begin title 25
Discussion
###end title 25
###begin p 26
###xml 241 246 241 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF.</italic>
###xml 477 481 477 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
An exploratory analysis of 1,433 SNPs in or near 386 genes involved in cancer-related pathways using the GoldenGate assay led to the identification of novel associations for several promising genes, the most notable finding, a 5' UTR SNP in VEGF. Subsequent analyses that captured nearly all common variants in this gene showed additional associations with SNPs in the promoter and intron 2, providing further evidence for the importance of variation in regulatory elements of VEGF and bladder cancer risk.
###end p 26
###begin p 27
###xml 47 51 47 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 128 132 128 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 221 225 221 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 294 295 294 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030029-b005">5</xref>
###xml 381 385 381 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 409 410 409 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030029-b006">6</xref>
###xml 676 677 676 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 790 791 790 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 791 792 791 792 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1058 1059 1058 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030029-b007">7</xref>
The association of common genetic variation in VEGF with bladder cancer risk is biologically plausible for several reasons: (1) VEGF has been identified as a critical factor in angiogenesis required for tumor growth, (2) VEGF expression in bladder tumors has been related to tumor progression [5], and (3) in vitro studies have suggested that common haplotypes in the 5' region of VEGF alter gene expression [6]. A large block of LD that extended from the promoter to intron 5 included the 5' UTR SNP (rs25648) that demonstrated the strongest association with bladder cancer risk in our initial screen. This SNP showed a departure from Hardy-Weinberg equilibrium in controls (p-value = 0.002), which was not observed for two correlated SNPs in the promoter region (rs1109324 and rs1547651; r2 > 0.80 between the 5' UTR and promoter SNPs) also associated with risk. We did not observe more deviations from Hardy-Weinberg equilibrium than expected by chance in our control population, the deviation for rs25648 was not observed in other Caucasian populations [7] (), and quality control samples did not show evidence for genotype errors; therefore, this departure is likely to have occurred by chance. The observed magnitude of the association for rs25648 was larger than for the two promoter SNPs; however, this difference was less apparent after re-estimation of ORs assuming Hardy-Weinberg equilibrium, suggesting that it might have occurred by chance.
###end p 27
###begin p 28
###xml 159 160 159 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030029-b006">6</xref>
###xml 537 538 537 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030029-b008">8</xref>
###xml 607 608 607 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030029-b009">9</xref>
###xml 609 611 609 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030029-b010">10</xref>
###xml 712 714 712 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030029-b011">11</xref>
###xml 773 775 773 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030029-b012">12</xref>
###xml 117 125 <span type="species:ncbi:9606">patients</span>
###xml 763 771 <span type="species:ncbi:9606">patients</span>
Carriers of the 5' UTR SNP (rs25648) have been found to have increased VEGF mRNA levels in adenocarcinoma tissues of patients with colorectal adenocarcinomas [6]. Although there are no functional studies of the two promoter SNPs associated with bladder cancer risk in our study population, previous studies have shown that variant genotypes or haplotypes falling in the same block of LD (rs699947, rs1570360, rs833061, and rs2010963) were associated with (1) higher induced gene expression from hypoxia in transient transfection assays [8]; (2) higher VEGF production in peripheral blood mononuclear cells [9,10]; (3) increased promoter activity and responsiveness to phorbol esters in breast cancer cell lines [11]; and (4) tumor aggressiveness in breast cancer patients [12]. Finally, the SNP in intron 2 (rs3024994) associated with reduced risk fell in the same block of LD but showed low correlation with other SNPs, and there are no published studies on its functional significance.
###end p 28
###begin p 29
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030029-b013">13</xref>
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030029-b014">14</xref>
###xml 136 144 <span type="species:ncbi:9606">patients</span>
Only one SNP in VEGF (rs699947) has been previously evaluated in relation to bladder cancer risk in a small study of 153 bladder cancer patients and 153 controls in South Korea [13]. Consistent with our results, this study found no association between this SNP and bladder cancer risk. A SNP in 3' of STP (rs3025039) has been associated with decreased plasma levels of VEGF and decreased breast cancer risk [14]; however, neither this nor other SNPs in LD were associated with bladder cancer risk in our study.
###end p 29
###begin p 30
We also observed promising associations with bladder cancer risk for other genes involved in carcinogenesis pathways. However, based on FDR calculations, taking into account all genes evaluated in this report, the additional associations were not robust and thus should be pursued in additional study populations.
###end p 30
###begin p 31
###xml 409 413 409 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
To the best of our knowledge, this is the first large-scale evaluation of candidate genes in bladder cancer using highly multiplexed technologies. Our data demonstrate that these technologies provide high quality data and that they can be useful in identifying genetic susceptibly factors. In particular, we provide reasonable evidence for an association between common variants in the promoter and 5' UTR of VEGF and bladder cancer risk. Further work is required to replicate the findings in other populations and to identify the potential causal variant by more detailed genetic mapping, including sequencing and functional characterization of variants.
###end p 31
###begin title 32
Materials and Methods
###end title 32
###begin title 33
Study population.
###end title 33
###begin p 34
###xml 52 53 52 53 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030029-b002">2</xref>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030029-b010">10</xref>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
###xml 298 306 <span type="species:ncbi:9606">patients</span>
The study population has been previously described [2]. Briefly, cases were patients participating in the Spanish Bladder Cancer Study diagnosed with histologically confirmed bladder carcinoma in 1998-2001, aged 21-80 y (mean [sd] = 66 [10] y), of which 87% were males. Controls were selected from patients admitted to participating hospitals for diagnoses believed to be unrelated to the exposures of interest, individually matched to the cases by age at interview within 5-y categories, gender, ethnicity, and region. Demographic and risk factor information was collected at the hospitals using computer-assisted personal interviews. A total of 1,219 cases (84% of eligible cases) and 1,271 controls (88% of eligible controls) agreed to participate in the study and were interviewed. Of these, 1,188 (97%) cases and 1,173 (92%) controls provided a blood or buccal cell sample for DNA extraction. Adequate amounts of DNA for genotyping were available from 1,116 cases (including eight from buccal cells) and 1,043 controls (including 36 from buccal cells). Further exclusions were made to reduce heterogeneity (cases with nontransitional histology and nonwhite subjects), or because of DNA contamination or lack of information on smoking status. After exclusions, the available samples for genotype analysis were 1,086 cases and 1,033 controls.
###end p 34
###begin p 35
###xml 44 56 <span type="species:ncbi:9606">participants</span>
We obtained informed consent from potential participants in accordance with the National Cancer Institute and local institutional review boards.
###end p 35
###begin title 36
Genotyping.
###end title 36
###begin p 37
###xml 198 199 198 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030029-b003">3</xref>
###xml 786 794 786 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0030029-st001">Table S1</xref>
A GoldenGate assay (Illumina, ) was developed using SNPs in the SNP500Cancer project () with previous re-sequence analysis and plausible evidence that the gene is related to carcinogenic processes [3]. SNP selection favored nonsynonymous SNPs, those previously evaluated in relation to cancer risk, or those with evidence for functional significance. The GoldenGate assay was designed to examine 1,536 SNPs based on an initial screen of 3,072 SNPs drawn from the SNP500Cancer database (November 2004) and subsequently analyzed in the unrelated HapMap Centre d'Etude du Polymorphisme Humain (CEPH) Utah samples. Of the 1,536 assays chosen for this study, 103 were dropped from the analysis because of low MAF or assay problems. Thus, we obtained data on 1,433 SNPs in or near 386 genes (Table S1). DNA samples from cases and controls were randomly sorted, including 69 duplicated DNA samples for genotyping quality control.
###end p 37
###begin p 38
###xml 101 106 101 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF,</italic>
###xml 299 303 299 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030029-b015">15</xref>
###xml 414 415 414 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 415 416 415 416 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Based on our primary analysis that showed the strongest association of bladder cancer with an SNP in VEGF, we performed a comprehensive evaluation of common variation in this gene. We initially selected 31 SNPs spanning 20 kb 5' of the start of transcription to 10 kb 3' of the end of exon 8 of the VEGF gene using the following methods: (1) 15 tag SNPs were chosen based on the aggressive tagging algorithm [15] (r2 >/= 0.80, MAF >/= 0.05) using genotype data from the unrelated HapMap CEPH Utah individuals; (2) 16 SNPs from the Single Nucleotide Polymorphism database were added as "fill-in" to ensure the inclusion of an SNP every 2-5 kb across the region, particularly in the 5' region. iPLEX (Sequenom, ) assays were designed and optimized with the SNP500Cancer set of 102 individuals. Two SNPs were dropped because of design and performance problems. Out of 29, 28 assays were optimized on iPLEX and one SNP (rs699947) that could not be included was analyzed using TaqMan (Applied Biosystems, ). Because of restricted amounts of DNA available and poor assay performance for a small subset of samples and exclusions for data analyses described earlier (cases with nontransitional histology, nonwhite subjects, and lack of information on smoking status), a total of 926 cases and 900 controls were included in the analyses.
###end p 38
###begin title 39
Statistical analysis.
###end title 39
###begin p 40
###xml 216 217 216 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030029-b002">2</xref>
###xml 781 785 781 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NAT2</italic>
###xml 790 795 790 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GSTM1</italic>
###xml 812 813 812 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030029-b002">2</xref>
For each individual SNP, we estimated OR and 95% CI using logistic regression models adjusting for gender, age at interview in 5-y categories, region, and smoking status (never, occasional, former, and current; see [2] for details on the definition of these variables). The association between individual SNPs and bladder cancer risk was tested using a 2-df LRT and a linear trend test assuming a dose response with increasing number of variant alleles. ORs and 95% CIs "per variant allele" were estimated under the latter assumption (i.e., coding genotypes as 0, 1, and 2 depending on the number of variant alleles). Heterogeneity of genotype ORs among groups of subjects defined by age, gender, smoking status, family history of cancer in at least one first-degree relative, and NAT2 and GSTM1 genotypes (see [2] for details on the definition of these variables) were evaluated by introducing interaction terms in logistic regression models.
###end p 40
###begin p 41
###xml 503 504 503 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 504 505 504 505 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 608 616 608 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0030029-st001">Table S1</xref>
The 1,433 individual SNPs evaluated were located within or near 386 candidate genes. We performed two gene-based tests for association: (1) an LRT for each gene comparing models with and without terms for heterozygous and homozygous variant genotypes for each SNP in a given gene (df = 2 x number of SNPs per gene); (2) an LRT for each gene comparing models with and without terms for each SNP (genotypes coded as 0, 1, and 2) in a given gene (df = number of SNPs per gene). For highly correlated SNPs (r2 > 0.90) within a gene, only one of the SNPs was included in the model to avoid collinearity problems (Table S1).
###end p 41
###begin p 42
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030029-b016">16</xref>
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030029-b017">17</xref>
Haplotype frequencies, ORs, and 95% CIs for genes showing blocks of LD were estimated using HaploStats (). This program reconstructs haplotypes and estimates ORs simultaneously based on a suitable Expectation-Maximization algorithm [16,17].
###end p 42
###begin p 43
###xml 82 83 82 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 180 181 180 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030029-b004">4</xref>
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030029-b018">18</xref>
###xml 260 262 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030029-b019">19</xref>
We used the method described by J. Chen and N. Chatterjee to obtain estimates and p-values for genotype associations assuming Hardy-Weinberg equilibrium in the control population [4]. Phylogenetic trees (neighbor joining [18]) were constructed using MEGA 3.1 [19] () to assess nucleotide similarity of different haplotypes.
###end p 43
###begin p 44
###xml 437 439 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030029-b020">20</xref>
We evaluated the robustness of our results using the FDR. FDR is the expected ratio of erroneous rejections of the null hypothesis to the total number of rejected hypothesis among all the genes or SNPs analyzed in this report. Rather than using an arbitrary threshold FDR value, we report the values for the most significant associations to allow the reader to evaluate the robustness of our findings. The Benjamini and Hochberg method [20] was used to calculate FDR values using "multtest" package in the R project for statistical analyses (). Unless otherwise specified, statistical analyses were performed with STATA Version 8.2, Special Edition (STATA Corporation, ).
###end p 44
###begin title 45
Supporting Information
###end title 45
###begin title 46
List of SNPs Included in the SNP500 Illumina GoldenGate Assay, Spanish Bladder Cancer Study
###end title 46
###begin p 47
(1.2 MB DOC).
###end p 47
###begin p 48
Click here for additional data file.
###end p 48
###begin title 49
###xml 76 77 76 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
SNP-Based Analyses: Association between Bladder Cancer Risk and SNPs with a p-value from a Trend Test or a 2-df LRT </= 0.01 in the Spanish Bladder Cancer Study
###end title 49
###begin p 50
(34 KB DOC).
###end p 50
###begin p 51
Click here for additional data file.
###end p 51
###begin title 52
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
Association between Common Variants in VEGF and Bladder Cancer Risk in the Spanish Bladder Cancer Study
###end title 52
###begin p 53
(233 KB DOC).
###end p 53
###begin p 54
Click here for additional data file.
###end p 54
###begin title 55
Genotype Cell Counts for Cases and Controls
###end title 55
###begin p 56
(19 KB XLS).
###end p 56
###begin p 57
Click here for additional data file.
###end p 57
###begin title 58
###xml 61 65 61 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 148 152 148 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NAT2</italic>
###xml 157 162 157 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GSTM1</italic>
Modification of the Association between Selected Variants in VEGF and Bladder Cancer Risk by Age, Gender, Smoking Status, Family History of Cancer, NAT2 and GSTM1 Genotypes
###end title 58
###begin p 59
(173 KB DOC).
###end p 59
###begin p 60
Click here for additional data file.
###end p 60
###begin title 61

###end title 61
###begin title 62
Accession Numbers
###end title 62
###begin p 63
###xml 79 86 79 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARHGDIB</italic>
###xml 94 99 94 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CASP9</italic>
###xml 107 111 107 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CETP</italic>
###xml 120 126 120 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 135 142 135 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP24A1</italic>
###xml 151 155 151 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1</italic>
###xml 164 168 164 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FZD7</italic>
###xml 177 180 177 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GHR</italic>
###xml 189 193 189 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GPX4</italic>
###xml 202 207 202 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GSTA4</italic>
###xml 216 222 216 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSD174</italic>
###xml 231 235 231 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LIPC</italic>
###xml 244 250 244 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PLA2G6</italic>
###xml 259 262 259 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTH</italic>
###xml 271 277 271 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RB1CC1</italic>
###xml 286 290 286 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ROS1</italic>
###xml 299 303 299 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SHBG</italic>
###xml 312 317 312 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STAT1</italic>
###xml 326 331 326 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STK11</italic>
###xml 340 344 340 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TERT</italic>
###xml 353 357 353 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 366 371 366 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC4</italic>
###xml 384 390 384 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ZNF350</italic>
The accession numbers for the Entrez Gene () genes discussed in this paper are ARHGDIB (397), CASP9 (842), CETP (1071), CYP1B1 (1545), CYP24A1 (1591), ESR1 (2099), FZD7 (8324), GHR (2690), GPX4 (2879), GSTA4 (2941), HSD174 (3295), LIPC (3990), PLA2G6 (8398), PTH (5741), RB1CC1 (9821), ROS1 (6098), SHBG (6462), STAT1 (6772), STK11 (6794), TERT (7015), VEGF (7422), XRCC4 (7518), and ZNF350 (59348).
###end p 63
###begin p 64
###xml 739 751 <span type="species:ncbi:9606">participants</span>
###xml 957 962 <span type="species:ncbi:9606">Human</span>
We thank Robert C. Saal from Westat, Rockville, Maryland and Leslie Carroll and Jane Wang from Information Management Services, Incorporated (IMS), Silver Spring, Maryland for their support in study and data management; Dr. Zeynep Kalaylioglu from IMS, Silver Spring, Maryland and Mr. Douglas Richerson from the Division of Cancer Epidemiology and Genetics, National Cancer Institute for their support in data analysis; Dr. Maria Sala from the Municipal Institute of Medical Research (IMIM), Barcelona, Spain for her work in data collection; Francisco Fernandez for his work on data management; Dr. Montserrat Tora for her work in the coordination of sample collection and blood processing; and physicians, nurses, interviewers, and study participants for their efforts during field work. Dr. Jonine Figueroa was supported by the Cancer Prevention Fellowship Program of the Division of Cancer Prevention, National Cancer Institute, Department of Health and Human Services.
###end p 64
###begin p 65
###xml 0 27 0 27 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Participating study centers</bold>
###xml 1434 1441 <span type="species:ncbi:113210">Manzano</span>
Participating study centers in Spain: Institut Municipal d'Investigacio Medica, Universitat Pompeu Fabra, Barcelona-Coordinating Center (M. Kogevinas, N. Malats, F. X. Real, M. Sala, G. Castano, M. Tora, D. Puente, C. Villanueva, C. Murta, J. Fortuny, E. Lopez, S. Hernandez, R. Jaramillo); Hospital del Mar, Universitat Autonoma de Barcelona, Barcelona (J. Lloreta, S. Serrano, L. Ferrer, A. Gelabert, J. Carles, O. Bielsa, K. Villadiego), Hospital Germans Tries i Pujol, Badalona, Barcelona (L. Cecchini, J. M. Saladie, L. Ibarz); Hospital de Sant Boi, Sant Boi, Barcelona (M. Cespedes); Centre Hospitalari Parc Tauli, Sabadell, Barcelona (C. Serra, D. Garcia, J. Pujadas, R. Hernando, A. Cabezuelo, C. Abad, A. Prera, J. Prat); ALTHAIA, Manresa, Barcelona (M. Domenech, J. Badal, J. Malet); Hospital Universitario, La Laguna, Tenerife (R. Garcia-Closas, J. Rodriguez de Vera, A. I. Martin); Hospital La Candelaria, Santa Cruz, Tenerife (J. Tano, F. Caceres); Hospital General Universitario de Elche, Universidad Miguel Hernandez, Elche, Alicante (A. Carrato, F. Garcia-Lopez, M. Ull, A. Teruel, E. Andrada, A. Bustos, A. Castillejo, J. L. Soto); Universidad de Oviedo, Oviedo, Asturias (A. Tardon); Hospital San Agustin, Aviles, Asturias (J. L. Guate, J. M. Lanzas, J. Velasco); Hospital Central Covadonga, Oviedo, Asturias (J. M. Fernandez, J. J. Rodriguez, A. Herrero), Hospital Central General, Oviedo, Asturias (R. Abascal, C. Manzano); Hospital de Cabuenes , Gijon, Asturias (M. Rivas, M. Arguelles); Hospital de Jove, Gijon, Asturias (M. Diaz, J. Sanchez, O. Gonzalez); Hospital de Cruz Roja, Gijon, Asturias (A. Mateos, V. Frade); Hospital Alvarez-Buylla Mieres, Asturias (P. Muntanola, C. Pravia); Hospital Jarrio, Coana, Asturias (A. M. Huescar, F. Huergo); and Hospital Carmen y Severo Ochoa, Cangas, Asturias (J. Mosquera).
###end p 65
###begin title 66
Abbreviations
###end title 66
###begin p 67
confidence interval
###end p 67
###begin p 68
degrees of freedom
###end p 68
###begin p 69
false discovery rate
###end p 69
###begin p 70
linkage disequilibrium
###end p 70
###begin p 71
likelihood ratio test
###end p 71
###begin p 72
minor allele frequency
###end p 72
###begin p 73
odds ratio
###end p 73
###begin p 74
single nucleotide polymorphism
###end p 74
###begin p 75
stop codon
###end p 75
###begin title 76
References
###end title 76
###begin article-title 77
Bladder cancer
###end article-title 77
###begin article-title 78
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NAT2</italic>
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GSTM1</italic>
NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: Results from the Spanish Bladder Cancer Study and meta-analyses
###end article-title 78
###begin article-title 79
SNP500Cancer: A public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes
###end article-title 79
###begin article-title 80
Exploiting Hardy-Weinberg equilibrium for efficient screening of single SNP associations from case-control studies
###end article-title 80
###begin article-title 81
Angiogenesis in bladder cancer: Prognostic marker and target for future therapy
###end article-title 81
###begin article-title 82
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
Association of VEGF genotype with mRNA level in colorectal adenocarcinomas
###end article-title 82
###begin article-title 83
Vascular endothelial growth factor gene haplotypes in Kawasaki disease
###end article-title 83
###begin article-title 84
###xml 53 57 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 71 75 71 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
DNA sequence variation in the promoter region of the VEGF gene impacts VEGF gene expression and maximal oxygen consumption
###end article-title 84
###begin article-title 85
Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection
###end article-title 85
###begin article-title 86
###xml 78 84 78 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(VEGF)</italic>
Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: Correlation with variation in VEGF protein production
###end article-title 86
###begin article-title 87
###xml 38 43 <span type="species:ncbi:9606">human</span>
Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter
###end article-title 87
###begin article-title 88
Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis
###end article-title 88
###begin article-title 89
###xml 13 43 13 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF-alpha, VEGF, hOGG1, GSTM1,</italic>
###xml 48 54 48 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GSTT1:</italic>
Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: Useful determinants for clinical outcome of bladder cancer
###end article-title 89
###begin article-title 90
A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels
###end article-title 90
###begin article-title 91
Selecting a maximally informative set of single nucleotide polymorphisms for association analyses using linkage disequilibrium
###end article-title 91
###begin article-title 92
Evaluating associations of haplotypes with traits
###end article-title 92
###begin article-title 93
Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous
###end article-title 93
###begin article-title 94
The neighbor-joining method: A new method for reconstructing phylogenetic trees
###end article-title 94
###begin article-title 95
MEGA3: Integrated software for molecular evolutionary genetics analysis and sequence alignment
###end article-title 95
###begin article-title 96
Controlling the false discovery rate: A practical and powerful approach to multiple testing
###end article-title 96
###begin p 97
A previous version of this article appeared as an Early Online Release on January 4, 2007 (doi:).
###end p 97
###begin p 98
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
###xml 360 367 <span type="species:ncbi:9606">patient</span>
Author contributions. MGC wrote the paper with contributions from all authors. MGC, JF, NC, and CMN analyzed the data. NC provided statistical advice. MGC, NM, FXR, MY, RW, NR, and SJC participated in gene selection. MY, RW, and SJC conceived and designed the experiments. MGC, NM, FXR, DS, MK, MD, AT, CS, AC, RGC, and NR participated in the study design and patient enrollment.
###end p 98
###begin p 99
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding.</bold>
Funding. This work was supported by the Intramural Research Program of the US National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics, and FIS/Spain grant numbers 00/0745, G03/174, G03/160, C03/09, and C03/10.
###end p 99
###begin p 100
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing interests.</bold>
Competing interests. The authors have declared that no competing interests exist.
###end p 100

